FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976534553> ?p ?o ?g. }

• W2976534553 endingPage "6870" @default.
• W2976534553 startingPage "6860" @default.
• W2976534553 abstract "Abstract Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective study was conducted to identify the most appropriate therapeutic strategy and prognosis‐related factors to predict the response of patients with relapsed or refractory MCL to ibrutinib monotherapy. Thirty‐three consecutive refractory or relapsed MCL patients treated with ibrutinib were analyzed in this study. The median overall survival (OS) and progression‐free survival (PFS) after initiation of ibrutinib were 35.1 months and 27.4 months, respectively. Risk factor analysis showed that high risk according to the Mantle Cell Lymphoma International Prognostic Index (MIPI) and nonresponse to ibrutinib at the first three cycles were significantly associated with inferior OS. Poor PFS was associated with high‐risk biologic MIPI, prior bendamustine exposure, and nonresponse to ibrutinib during the first three cycles. After ibrutinib failure, primary nonresponders had poorer OS and PFS than inconsistent responders. The overall response rate for the first salvage therapy was only 33%, with a median TTP of 3.2 months. There was no effective therapeutic strategy except for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Although ibrutinib responders exhibited favorable survival outcomes, nonresponders had a dismal prognosis. To overcome these limitations, it may be necessary to modify therapeutic strategies, such as selecting inconsistent responders for earlier allo‐HSCT." @default.
• W2976534553 created "2019-10-03" @default.
• W2976534553 creator A5011808819 @default.
• W2976534553 creator A5013163283 @default.
• W2976534553 creator A5021692797 @default.
• W2976534553 creator A5025200007 @default.
• W2976534553 creator A5028295485 @default.
• W2976534553 creator A5034751203 @default.
• W2976534553 creator A5036020306 @default.
• W2976534553 creator A5044372572 @default.
• W2976534553 creator A5067818349 @default.
• W2976534553 creator A5068585684 @default.
• W2976534553 creator A5069563388 @default.
• W2976534553 creator A5074128691 @default.
• W2976534553 creator A5080353333 @default.
• W2976534553 creator A5084426605 @default.
• W2976534553 creator A5085429434 @default.
• W2976534553 date "2019-09-27" @default.
• W2976534553 modified "2023-10-09" @default.
• W2976534553 title "Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience" @default.
• W2976534553 cites W1829587101 @default.
• W2976534553 cites W1977342543 @default.
• W2976534553 cites W1995920800 @default.
• W2976534553 cites W2021130630 @default.
• W2976534553 cites W2028681024 @default.
• W2976534553 cites W2029511375 @default.
• W2976534553 cites W2040410729 @default.
• W2976534553 cites W2053292153 @default.
• W2976534553 cites W2111259842 @default.
• W2976534553 cites W2112023756 @default.
• W2976534553 cites W2119147717 @default.
• W2976534553 cites W2121960517 @default.
• W2976534553 cites W2124432094 @default.
• W2976534553 cites W2130669641 @default.
• W2976534553 cites W2131900456 @default.
• W2976534553 cites W2154066874 @default.
• W2976534553 cites W2163690533 @default.
• W2976534553 cites W2190884983 @default.
• W2976534553 cites W2237195636 @default.
• W2976534553 cites W2311402280 @default.
• W2976534553 cites W2748428998 @default.
• W2976534553 cites W2790333200 @default.
• W2976534553 cites W2791154088 @default.
• W2976534553 cites W2794404663 @default.
• W2976534553 cites W2800598667 @default.
• W2976534553 doi "https://doi.org/10.1002/cam4.2565" @default.
• W2976534553 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6853811" @default.
• W2976534553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31560165" @default.
• W2976534553 hasPublicationYear "2019" @default.
• W2976534553 type Work @default.
• W2976534553 sameAs 2976534553 @default.
• W2976534553 citedByCount "17" @default.
• W2976534553 countsByYear W29765345532020 @default.
• W2976534553 countsByYear W29765345532021 @default.
• W2976534553 countsByYear W29765345532022 @default.
• W2976534553 countsByYear W29765345532023 @default.
• W2976534553 crossrefType "journal-article" @default.
• W2976534553 hasAuthorship W2976534553A5011808819 @default.
• W2976534553 hasAuthorship W2976534553A5013163283 @default.
• W2976534553 hasAuthorship W2976534553A5021692797 @default.
• W2976534553 hasAuthorship W2976534553A5025200007 @default.
• W2976534553 hasAuthorship W2976534553A5028295485 @default.
• W2976534553 hasAuthorship W2976534553A5034751203 @default.
• W2976534553 hasAuthorship W2976534553A5036020306 @default.
• W2976534553 hasAuthorship W2976534553A5044372572 @default.
• W2976534553 hasAuthorship W2976534553A5067818349 @default.
• W2976534553 hasAuthorship W2976534553A5068585684 @default.
• W2976534553 hasAuthorship W2976534553A5069563388 @default.
• W2976534553 hasAuthorship W2976534553A5074128691 @default.
• W2976534553 hasAuthorship W2976534553A5080353333 @default.
• W2976534553 hasAuthorship W2976534553A5084426605 @default.
• W2976534553 hasAuthorship W2976534553A5085429434 @default.
• W2976534553 hasBestOaLocation W29765345531 @default.
• W2976534553 hasConcept C121332964 @default.
• W2976534553 hasConcept C126322002 @default.
• W2976534553 hasConcept C142424586 @default.
• W2976534553 hasConcept C143998085 @default.
• W2976534553 hasConcept C2776694085 @default.
• W2976534553 hasConcept C2777525834 @default.
• W2976534553 hasConcept C2777938653 @default.
• W2976534553 hasConcept C2778461978 @default.
• W2976534553 hasConcept C2778476033 @default.
• W2976534553 hasConcept C2779338263 @default.
• W2976534553 hasConcept C2779878957 @default.
• W2976534553 hasConcept C2780653079 @default.
• W2976534553 hasConcept C2780775027 @default.
• W2976534553 hasConcept C2781442060 @default.
• W2976534553 hasConcept C71924100 @default.
• W2976534553 hasConcept C87355193 @default.
• W2976534553 hasConceptScore W2976534553C121332964 @default.
• W2976534553 hasConceptScore W2976534553C126322002 @default.
• W2976534553 hasConceptScore W2976534553C142424586 @default.
• W2976534553 hasConceptScore W2976534553C143998085 @default.
• W2976534553 hasConceptScore W2976534553C2776694085 @default.
• W2976534553 hasConceptScore W2976534553C2777525834 @default.
• W2976534553 hasConceptScore W2976534553C2777938653 @default.
• W2976534553 hasConceptScore W2976534553C2778461978 @default.
• W2976534553 hasConceptScore W2976534553C2778476033 @default.

• next